

CATABASIS PHARMACEUTICALS INC  
Form SC 13G/A  
January 17, 2019

**SECURITIES  
AND  
EXCHANGE  
COMMISSION  
Washington,  
D.C. 20549**

**SCHEDULE  
13G**

Under the  
Securities  
Exchange Act of  
1934

(Amendment No.  
1)\*

Catabasis  
Pharmaceuticals,  
Inc.  
(Name of Issuer)

Common Stock,  
\$0.001 par value  
(Title of Class of  
Securities)

14875P206  
(CUSIP Number)

December 31,  
2018  
(Date of event  
which requires  
filing of this  
statement)

Check the  
appropriate box  
to designate the  
rule pursuant to  
which this

Schedule 13G is  
filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

(Page 1 of 6  
Pages)

---

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 14875P206 13G/A Page 2 of 6 Pages

<b>1</b>	NAMES OF REPORTING PERSONS
<b>2</b>	Empery Asset Management, LP CHECK THE APPROPRIATE BOX IF A MEMBER (b) "
<b>3</b>	OF A GROUP SEC USE ONLY CITIZENSHIP OR PLACE OF
<b>4</b>	ORGANIZATION
<b>5</b>	Delaware SOLE VOTING POWER
<b>6</b>	499,999 shares of Common Stock issuable upon exercise of Warrants
<b>7</b>	SOLE DISPOSITIVE POWER
<b>8</b>	SHARED DISPOSITIVE POWER
	499,999 shares of Common Stock issuable upon exercise

of Warrants

AGGREGATE  
AMOUNT  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON

9

499,999 shares of  
Common Stock  
issuable upon exercise  
of Warrants

CHECK BOX  
IF THE  
AGGREGATE  
AMOUNT IN ..  
ROW (9)

10

EXCLUDES  
CERTAIN  
SHARES  
PERCENT OF  
CLASS  
REPRESENTED BY  
AMOUNT IN ROW  
(9)

11

0.70% (See Item 4)  
TYPE OF  
REPORTING  
PERSON

12

PN

CUSIP No. 14875P206 13G/A Page 3 of 6 Pages

<b>1</b>	NAMES OF REPORTING PERSONS
	Ryan M. Lane
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER (b) " OF A GROUP
<b>3</b>	SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
<b>5</b>	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
	SOLE VOTING POWER
	SHARED VOTING POWER
<b>6</b>	499,999 shares of Common Stock issuable upon exercise of Warrants
<b>7</b>	SOLE DISPOSITIVE POWER
<b>8</b>	SHARED DISPOSITIVE POWER
	499,999 shares of Common Stock issuable upon exercise of Warrants

AGGREGATE  
AMOUNT  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON

**9**

499,999 shares of  
Common Stock  
issuable upon exercise  
of Warrants

CHECK BOX  
IF THE  
AGGREGATE  
AMOUNT IN ..

**10**

ROW (9)  
EXCLUDES  
CERTAIN  
SHARES  
PERCENT OF  
CLASS  
REPRESENTED BY  
AMOUNT IN ROW  
(9)

**11**

0.70% (See Item 4)  
TYPE OF  
REPORTING  
PERSON

**12**

IN

CUSIP No. 14875P206 13G/A Page 4 of 6 Pages

<b>1</b>	NAMES OF REPORTING PERSONS
	Martin D. Hoe
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER (b) " OF A GROUP
<b>3</b>	SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
<b>5</b>	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
	SOLE VOTING POWER
	SHARED VOTING POWER
<b>6</b>	499,999 shares of Common Stock issuable upon exercise of Warrants
<b>7</b>	SOLE DISPOSITIVE POWER
<b>8</b>	SHARED DISPOSITIVE POWER
	499,999 shares of Common Stock issuable upon exercise of Warrants

AGGREGATE  
AMOUNT  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON

**9**

499,999 shares of  
Common Stock  
issuable upon exercise  
of Warrants

CHECK BOX  
IF THE  
AGGREGATE  
AMOUNT IN ..

**10**

ROW (9)  
EXCLUDES  
CERTAIN  
SHARES  
PERCENT OF  
CLASS  
REPRESENTED BY  
AMOUNT IN ROW  
(9)

**11**

0.70% (See Item 4)  
TYPE OF  
REPORTING  
PERSON

**12**

IN



**CUSIP No. 14875P206 13G/A Page 5 of 6 Pages**

This Amendment No. 1 (this "Amendment") amends the statement on Schedule 13G filed on June 25, 2018 (the "Original Schedule 13G" and the Original Schedule 13G as amended, the "Schedule 13G"), with respect to shares of Common Stock, \$0.001 par value (the "Common Shares"), of Catabasis Pharmaceuticals, Inc. (the "Company"). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Schedule 13G. This Amendment amends and restates Items 2(e), 4 and 5 in their entirety as set forth below.

**Item 2(e). CUSIP NUMBER:**

14875P206

**Item 4. OWNERSHIP.**

The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 71,038,419 shares of Common Stock issued and outstanding on October 31, 2018, as represented in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2018 and assumes the exercise of the Company's reported warrants (the "Reported Warrants").

The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants held by the Empery Funds. Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants held by the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

**Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

**CUSIP No. 14875P206 13G/A Page 6 of 6 Pages**

**SIGNATURES**

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: January 17, 2019

EMPERY ASSET  
MANAGEMENT,  
LP  
By: EMPERY AM  
GP, LLC, its General  
Partner

By: /s/ Ryan M. Lane  
Name: Ryan M.  
Lane  
Title: Managing  
Member

/s/ Ryan M. Lane  
Ryan M. Lane

/s/ Martin D. Hoe  
Martin D. Hoe